Brief: Eisai Submits Marketing Authorisation Variation To EMA For Intravenous Maintenance Dosing With Leqembi
26/01/2026 21:03
Jan 26 (Reuters) - Bioarctic Ab BIOAb.ST: EISAI SUBMITS MARKETING AUTHORISATION VARIATION TO EMA FOR INTRAVENOUS MAINTENANCE DOSING EVERY FOUR WEEKS WITH LEQEMBI® (LECANEMAB) Source text: ID:nWkr9RC9Z8 Further company coverage: BIOAb.ST ((Reuters.Briefs@thomsonreuters.com;))
Recent news on BioArctic AB
See all newsBrief: BioArctic And Lilly Sign Research, Collaboration Agreement
Brief: Bioarctic AB Declares Dividend Of Sek 2 Per Share With 1 June 2026 Record Date
Brief: Bioarctic Partner Eisai Presents Leqembi Sales Simulation
Sweden's BioArctic Q1 revenue drops sharply despite higher Leqembi royalties
Brief: BioArctic Q1 Operating Profit SEK 210.8 Million